Traders assign an 88.5% probability to “No” on a new COVID variant of concern before 2027 because global surveillance through mid-2026 shows no variants meeting WHO or ECDC VOC criteria. Omicron sublineages such as XFG and NB.1.8.1 dominate circulation at low overall incidence, while heavily mutated candidates like BA.3.2 (Cicada) have spread to multiple countries yet remain classified only as variants under monitoring with minimal prevalence and no notable rise in severity or immune escape. Recent ECDC updates confirm zero active VOCs, and the remaining five months offer limited window for a new lineage to emerge, spread widely, and trigger formal designation. Continued genomic monitoring and stable case trends reinforce the market’s view that significant escalation is unlikely in this timeframe.